https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2005-12-01 / Pathology 2005 Dec;37(6):534-50
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2005-12-01 / Pathology 2005 Dec;37(6):534-502005-12-01 00:00:002019-02-15 08:51:27Vaccine strategies to treat lymphoproliferative disorders
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2005-10-07 / Hum. Immunol. 2005 Sep;66(9):938-49
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2005-10-07 / Hum. Immunol. 2005 Sep;66(9):938-492005-10-07 00:00:002019-02-15 09:25:40Dendritic cells expand Epstein Barr virus specific CD8+ T cell responses more efficiently than EBV transformed B cells
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2005-10-01 / Curr Gene Ther 2005 Oct;5(5):511-21
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2005-10-01 / Curr Gene Ther 2005 Oct;5(5):511-212005-10-01 00:00:002019-02-15 09:25:41Genetic idiotypic and tumor cell-based vaccine strategies for indolent non Hodgkin’s lymphoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2005-09-26 / Clin. Immunol. 2006 Jan;118(1):66-76
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2005-09-26 / Clin. Immunol. 2006 Jan;118(1):66-762005-09-26 00:00:002019-02-15 09:25:38B cell tumor vaccine enhanced by covalent attachment of immunoglobulin to surface proteins on dendritic cells
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2005-09-01 / J. Immunother. 2005 Sep-Oct;28(5):461-6
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2005-09-01 / J. Immunother. 2005 Sep-Oct;28(5):461-62005-09-01 00:00:002019-02-15 09:25:43B-cell lymphoma and myeloma protection induced by idiotype vaccination with dendritic cells is mediated entirely by T cells in mice
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2005-08-01 / Br. J. Haematol. 2005 Aug;130(3):344-62
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2005-08-01 / Br. J. Haematol. 2005 Aug;130(3):344-622005-08-01 00:00:002019-02-15 09:25:43Immunotherapy in multiple myeloma–possibility or probability?
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2005-07-15 / Cancer Immunol. Immunother. 2006 Apr;55(4):420-32
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2005-07-15 / Cancer Immunol. Immunother. 2006 Apr;55(4):420-322005-07-15 00:00:002019-02-15 09:25:37Adjuvant IL-15 does not enhance the efficacy of tumor cell lysate-pulsed dendritic cell vaccines for active immunotherapy of T cell lymphoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2005-07-01 / J. Immunother. 2005 Jul-Aug;28(4):322-31
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2005-07-01 / J. Immunother. 2005 Jul-Aug;28(4):322-312005-07-01 00:00:002019-02-15 09:25:44Immunoselection of functional CMRF-56+ blood dendritic cells from multiple myeloma patients for immunotherapy
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2005-07-01 / Cancer Res. 2005 Jul;65(13):5958-64
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2005-07-01 / Cancer Res. 2005 Jul;65(13):5958-642005-07-01 00:00:002019-02-15 09:25:45Therapeutic vaccination against murine lymphoma by intratumoral injection of naive dendritic cells
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2005-06-01 / Curr Opin Investig Drugs 2005 Jun;6(6):597-604
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2005-06-01 / Curr Opin Investig Drugs 2005 Jun;6(6):597-6042005-06-01 00:00:002019-02-15 09:25:46Vaccine therapy for non-Hodgkin’s lymphoma and other B-cell malignancies
